Liposomal-Based Formulations: A Path from Basic Research to Temozolomide Delivery Inside Glioblastoma Tissue
Glioblastoma (GBM) is a lethal brain cancer with a very difficult therapeutic approach and ultimately frustrating results. Currently, therapeutic success is mainly limited by the high degree of genetic and phenotypic heterogeneity, the blood brain barrier (BBB), as well as increased drug resistance....
Saved in:
Main Authors: | Roxana-Maria Amarandi (Author), Alina Ibanescu (Author), Eugen Carasevici (Author), Luminita Marin (Author), Brindusa Dragoi (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Erythromycin Formulations-A Journey to Advanced Drug Delivery
by: Vera-Maria Platon, et al.
Published: (2022) -
Targeted Delivery of Liposomal Temozolomide Enhanced Anti-Glioblastoma Efficacy through Ultrasound-Mediated Blood-Brain Barrier Opening
by: Zhuqing Song, et al.
Published: (2021) -
Advances in the management of glioblastoma: the role of temozolomide and MGMT testing
by: Thomas RP, et al.
Published: (2012) -
Modified Adenosines Sensitize Glioblastoma Cells to Temozolomide by Affecting DNA Methyltransferases
by: Maria Chiara Proto, et al.
Published: (2022) -
Aberrant Expression of ADARB1 Facilitates Temozolomide Chemoresistance and Immune Infiltration in Glioblastoma
by: Can Lu, et al.
Published: (2022)